drugset / Trial / NCT07862647

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

NCT07862647 ↗

Phase 1 Recruiting 30 enrolled Alpheus Medical, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

Timeline

Start
2026-10-29
Primary completion
2027-10-30
Completion
2028-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent — Oral

Indications